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Lithium alters expression of 
RNAs in a type-specific manner 
in differentiated human 
neuroblastoma neuronal cultures, 
including specific genes involved in 
Alzheimer’s disease
Bryan Maloney  1,5, Yokesh Balaraman1,5, Yunlong Liu2, nipun chopra1,  
Howard J. edenberg  2,3, John Kelsoe  4, John i. nurnberger1,3 & Debomoy K. Lahiri  1,3*
Lithium (Li) is a medication long-used to treat bipolar disorder. It is currently under investigation for 
multiple nervous system disorders, including Alzheimer’s disease (AD). While perturbation of RNA 
levels by Li has been previously reported, its effects on the whole transcriptome has been given little 
attention. We, therefore, sought to determine comprehensive effects of Li treatment on RNA levels. 
We cultured and differentiated human neuroblastoma (SK-N-SH) cells to neuronal cells with all-trans 
retinoic acid (ATRA). We exposed cultures for one week to lithium chloride or distilled water, extracted 
total RNA, depleted ribosomal RNA and performed whole-transcriptome RT-sequencing. We analyzed 
results by RNA length and type. We further analyzed expression and protein interaction networks 
between selected Li-altered protein-coding RnAs and common AD-associated gene products. Lithium 
changed expression of RNAs in both non-specific (inverse to sequence length) and specific (according 
to RnA type) fashions. the non-coding small nucleolar RnAs (snoRnAs) were subject to the greatest 
length-adjusted Li influence. When RNA length effects were taken into account, microRNAs as a group 
were significantly less likely to have had levels altered by Li treatment. Notably, several Li-influenced 
protein-coding RNAs were co-expressed or produced proteins that interacted with several common 
AD-associated genes and proteins. Lithium’s modification of RNA levels depends on both RNA length 
and type. Li activity on snoRNA levels may pertain to bipolar disorders while Li modification of protein 
coding RNAs may be relevant to AD.
Lithium (Li) has been used to effectively treat bipolar disorder for more than 60 years1. Li may affect cellular sign-
aling processes and promote long-term neuroplasticity2,3. Li also seems to have neurotrophic properties affecting 
cell survival and apoptosis mechanisms4, and trace levels may to some extent prevent dementia5, suicide6, and 
homicide7. The breadth of effects for Li suggest that the metal may be a trace nutrient8. In particular, Li levels 
in drinking water correlated with reduced age-adjusted Alzheimer’s disease (AD) mortality9 and incidence10. 
Several investigations of using Li to treat AD or specific symptoms associated with AD are ongoing11–14. However, 
Li toxicity produces Parkinson’s disease (PD) - and AD-like outcomes. Li is currently under active investigation 
for a broad array of psychiatric and neurological disorders (including AD, Niemann-Pick disease, frontotemporal 
dementia, and ALS), as well as gastrointestinal disease, neoplasia, and other non-neurological conditions. As of 
June 11, 2019, the US National Institutes of Health (NIH) lists 141 planned, recruiting, or active clinical trials for 
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Li effects on psychiatric and nervous system disorders, along with an additional 104 for conditions that do not 
involve the nervous system (http://www.clinicaltrials.gov).
The mechanisms underlying lithium therapeutic activity are still not clear15,16. Three principal hypotheses are 
its action on i) cyclic AMP17,18, ii) inositol depletion19, and iii) the inhibition of protein kinases, including glyco-
gen synthase kinase, with subsequent activation of the wnt neurodevelopmental pathway20,21. Li also increases 
levels of the anti-apoptotic protein Bcl2 in the frontal cortex of rat brain22. Li displays general neuroprotective 
effects, including against excitotoxic lesions23 as well as protection against β-amyloid induced cell death24. Li 
increases N-acetyl-aspartate levels in human brain (a measure of neuronal viability) during therapeutic treat-
ment, as measured by magnetic resonance spectroscopy25. This increase appears to be related to increases in grey 
matter volume26. Li, similarly to antidepressants, increases hippocampal neurogenesis27. Nevertheless, multiple 
clinical effects of Li are not entirely explained by prevailing theories28. Use of neuronally-differentiated pluri-
potent stem cells from bipolar patients who were responsive to Li vs non-responders revealed that neuronal 
hyperactivity responded to Li in responders but not in non-responders29,30. It should be noted that these cells, 
even though taken from living patients, represent early developmental stages of central nervous system (CNS) 
cells. Changes in adult neuronal cells from Li-responsive patients may be related to decreased phosphorylation of 
collapsin response mediator protein-2 (CRMP2) and increased dendritic spine density31.
Since so many pathways are apparently involved in Li treatment of bipolar disorder, and the pathways associ-
ated with possible Li treatment of other disorders, such as AD, are yet unknown, a reasonable question is how Li 
alters the transcriptome. Gene expression changes induced by Li treatment exist in both neuronal cultures and 
animals32–35. However, those reports were array-based assays, not whole transcriptome surveys. If a specific RNA 
were not a priori included on an array, Li effects on it would not be measured. Thus, we performed whole transcrip-
tome sequencing of Li-treated vs. untreated cells. Neuronal cell lines have the advantage of standardization of bio-
chemical characteristics, ease of adaptation to multiple experimental protocols, and simulation of adult CNS cells’ 
chemical and physiologic characteristics. We found that Li changes expression of multiple small RNA species, par-
ticularly non-coding small nucleolar RNAs (snoRNA), in all-trans retinoic acid (ATRA) differentiated human neu-
roblastoma neuronal (SK-N-SH) culture, but that small RNA species do not all respond to Li stimulation equally.
The snoRNAs may function in multiple neurobiological disorders and symptoms, including catatonia36. 
snoRNA levels differed between schizophrenic and control subjects in the anterior cingulate cortex37,38. snoRNA 
may also play a role in some features of autism39,40. Finally, specific snoRNAs undergo progressive changes with 
age41, and snoRNA levels vary with progressing Braak stages in AD42. We, therefore, investigated potential con-
nections among Li-perturbed genes and AD-associated genes and proteins. Our results generated interaction net-
works that can inform future mechanistic research, relevant to AD, bipolar and other neuropsychiatric disorders.
Results
cell culture response. No gross differences in cell morphology or survival were noted.
Small RNAs, particularly small nucleolar RNAs are over-represented among Li-influenced 
genes. We treated neuronally differentiated human cell cultures with Li and measured relative change vs. 
vehicle (distilled water)-treated cells in RNA levels, detected by whole-transcriptome sequencing. We found that 
log lengths of whole transcriptome sequencing had a bimodal distribution. Parameterized Gaussian mixture 
model43,44, cluster centers corresponded to 87 nucleotides (range 22 to 213) and 3047 nucleotides (range 233 
to 116,854) in length (Fig. 1A, Table 1). Li significantly altered the expression of 207 RNA species of 15,394 
sequenced (Supplementary Table 1) at a false discovery rate (FDR) ≤ 0.2, making Li influence an uncommon 
event. We did not consider magnitude of influence in our analysis, although the lowest absolute magnitude of 
change for RNA sequences with FDR ≤ 0.2 was −20% (Supplementary Table 2). Comparing the distribution of 
altered vs. non-altered sequences indicated that shorter RNA sequences predominated in the Li-influenced group 
(Fig. 1B), while relative distribution of non-influenced sequence lengths was more similar to the distribution of 
all sequence lengths (Fig. 1C). Of the 207 Li-influenced RNAs, 103 (49.8%) were in the “short” cluster vs 1031 of 
15187 (6.8%) non-influenced RNAs.
RNA species influenced response to Li. To investigate whether the difference simply reflected RNA 
transcript length or was also influenced by RNA species/type, we used logistic regression to model presence/
absence of Li alteration by type of RNA and sequence length. The optimal model derived was “Li influenced ~ 
log(Length) + RNA Type”. We discovered an odds ratio (OR) of 0.729 +0.226/−0.171 (p ≤ 0.05) for log RNA 
length vs. Li influence, irrespective of RNA type, i.e., as RNA length decreased, likelihood of Li influence increased.
Of greater interest, we found that Li treatment had significantly different effects among RNA types/species, 
independent of sequence length. Two species (Small NF90 (ILF3) associated RNAs/snaRNA and vault RNA/
vtRNA) were each represented in our sample by a single sequence. We excluded both RNA types from further 
analysis. When compared to overall levels of perturbation across all RNA types (effect coding), levels of 4 types 
were significantly more likely (OR > 1, p ≤ 0.05) to be altered by Li (Table 2), independently of RNA sequence 
length; specifically, small Cajal body-specific RNAs (scaRNA), 38% of scaRNA sequences; small nucleolar 
RNAs, H/ACA box (snoRA), 33% of snoRA sequences; small nucleolar RNAs, C/D box (snoRD), 30% of snoRD 
sequences; and small nuclear RNAs (snRNA), 22% of snRNA sequences. Levels of 4 types were significantly 
less likely (OR < 1, p ≤ 0.05) to be altered by Li treatment, specifically microRNA (miRNA), 1.7% of miRNA 
sequences; uncharacterized open reading frames (orf), 0.9% of orf sequences; protein coding RNA (coding), 0.7% 
of coding sequences; and antisense non-coding RNA (asncRNA), 0.6% of asncRNA sequences. To distinguish 
specific differences among the RNA species, we performed pairwise comparisons of ORs by RNA types, adjusted 
by FDR45 and found three overlapping groups (Fig. 2).
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We also investigated whether a given RNA species would be more likely to be upregulated or downregulated 
by Li treatment. We found that snRNA, snoRD, snoRA, and scaRNA were all significantly (p < 0.05) likely to 
have elevated levels after Li treatment (vs. reduced levels), while other RNA species had no significant effect 
(Table 3).
Figure 1. Size distribution of transcriptome, and relative distributions of Li-influenced vs. non-influenced 
transcriptome, and mean log-lengths of Li-influenced/-non-influenced RNAs. Both histograms and kernel 
density estimations44 of the distributions are shown. (A) Sequence frequencies by logarithms of sequence 
lengths. Log-lengths have a bimodal distribution with parameterized Gaussian mixture model clusters indicated 
as “Short” and “Long” and specific parameters in Table 1. (B–C) Sequences were separated by whether or not 
expression levels were altered by Li treatment. Relative frequencies within each group (Li-influenced vs. non-
influenced) were calculated by dividing counts by each group’s respective total number of sequences and plotted 
vs log(length). (B) Frequency of Li-altered RNAs by length. Line is corresponding kernel density estimation. (C) 
Frequency of non-influenced RNAs by length. Line is corresponding kernel density estimation.
Cluster Center (log)a
Minimum 
(log) Maximum (log)
Short 87 (1.938) 22 (1.342) 213 (2.328)
Long 3047 (3.484) 233 (2.367) 116,854 (5.068)
Table 1. Gaussian mixture model clustering of transcriptome sequence lengths. aLog figures are mean of logs. 
All analysis was done on logs of lengths.
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Li altered levels of specific protein-coding mRNAs and snoRNAs potentially associated with 
AD. Although the majority of Li influence concentrated on small, noncoding RNAs, several protein-coding 
mRNAs influenced by Li in this study play a role in AD (Table 3). The genes are involved in several Gene Ontology 
biological functions, predominately biological regulation (GO:0065007) and metabolic processes (GO:0008152). 
We created two networks (human hippocampus gene co-expression and human hippocampus gene product 
interaction) using these genes plus a selection of “core” AD-related genes (Table 4). Networks showed sev-
eral connections between the Li-influenced genes and AD-related genes. However, all such connections were 
second-degree, i.e., any AD-related gene did not co-express directly with a Li-influenced gene. Instead, a third 
gene co-expressed with both the AD-related gene and the Li-influenced gene (Fig. 3). On the other hand, when 
we built the protein-protein network, peroxisome proliferator-activated receptor γ (PPARγ), and SRY-related 
HMG-box 5 (SOX5) transcription factor directly interacted with the amyloid-β (Aβ) precursor protein (APP), 
Speciesa Total
Li Effect
percent ± SE
Logistic Modelingbc
Trendc.altered not ORd p groupe
snaRNAd 1 0 1 0.00% ± 0.00% na na na na
asncRNA 324 2 322 0.62% ± 0.44% 0.21 +0.45/−0.17 0.023 C Down
coding 13315 93 13222 0.70% ± 0.07% 0.28 +0.24/−0.13 <0.001 C Up
orf 583 5 578 0.86% ± 0.38% 0.29 +0.40/−0.19 0.009 C Down
pseudo 165 2 163 1.21% ± 0.85% 0.43 +0.92/−0.35 0.215 C Up
lincRNA 235 3 232 1.28% ± 0.73% 0.45 +0.79/−0.33 0.172 BC Up
miRNA 471 8 463 1.70% ± 0.60% 0.22 +0.27/−0.13 <0.001 BC None
snRNA 9 2 7 22.22% ± 13.86% 3.47 +10.71/−2.89 0.110 AB Up*
snoRD 175 52 123 29.71% ± 3.45% 5.32 +4.76/−2.46 <0.001 A Up*
snoRA 91 30 61 32.97% ± 4.93% 7.29 +6.03/−3.26 <0.001 A Up*
scaRNA 24 9 15 37.50% ± 9.88% 9.95 +12.83/−5.76 <0.001 A Up*
vtRNAd 1 1 0 100.00% ± 0.00% na na na na
Sum 15394 207 15187 1.36% na na na na
Table 2. RNA types influenced by Li treatment. aasncRNA: antisense noncoding RNA; coding: protein 
coding mRNA; lincRNA: long intergenic noncoding RNA; miRNA: micro-RNA; orf: uncharacterized RNA 
(open reading frame); pseudo: pseudogene RNA; scaRNA: small Cajal body specific RNA; snaRNA: small 
NF90 (ILF3) associated RNA; snoRA: small nucleolar RNAs, H/ACA box; snoRD: small nucleolar RNAs, 
C/D boxsnRNA: small nuclear RNA; vtRNA: vault RNA. bModel coded to test the hypothesis of whether or 
coefficient differs from the mean of groups. It is appropriate for multiple pairwise comparisons. cDerived from 
multinomial logistic modeling of Type + log(Length) vs. whether Li treatment significantly reduced, elevated, or 
had no effect on FC transcript levels. “*” indicates difference was significant at p < 0.05. dOR is for effect of RNA 
type from the model (Li Effect) ~ log(Length) + (RNA Type). ± is 95% confidence intervals. OR marked “*” 
were significantly different from zero. eMarginal means statistical group, FDR corrected. RNA species sharing 
letter did not significantly differ in odds of being altered by Li treatment, independent of RNA sequence length 
effect. dExcluded from logistic model.
Figure 2. Frequency/likelihood of Li alteration of RNA levels by type and relative distribution of small non-
coding RNA species between Li-influenced vs. non-influenced “short” cluster RNAs. Estimated probabilities of 
alteration of RNA levels by RNA type, taking effect of transcript length into account. Estimated model log odds 
ratios were compared and pairwise comparison p values adjusted by FDR45. RNA types sharing a letter did not 
differ at p ≤ 0.05. Pseudo R2 is Efron’s.
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along with SNORD14C (Fig. 4). Paradoxically, none of the snoRNAs associated with Braak staging (Table 5) 
appeared in either network. Thus, while Li may not directly modify expression of the better-known AD genes, a 
multi-target effect converging on APP could explain why micro-dosing may be effective, since APP could be the 
recipient of multiple outcome chains of Li activity.
Discussion
We demonstrated two effects of Li treatment on the whole RNA transcriptome of a human neuronal cell line. 
First, Li treatment is more likely to perturb levels of a given RNA inversely to its sequence length, regardless of 
RNA type. Second, and more importantly, specific RNA type exerts a significant influence on whether or not Li 
treatment perturbs its levels. That is, snoRNAs of three types (snoRD, snoRA, and scaRNA) are all significantly 
more likely to be perturbed while miRNA is significantly less likely to be perturbed. It is particularly noteworthy 
that miRNAs, although often of the same approximate length as snoRNAs, were significantly less likely to have 
levels perturbed by Li treatment.
SnoRNAs act as a guide in processing nuclear and ribosomal RNAs46,47. The functions of snoRNAs may 
extend to regulation of alternative splicing, gene silencing, chromatin modification and may even exhibit 
miRNA-like function48–54. Understanding the role of snoRNAs in behavior and disease conditions is also emerg-
ing. Prader-Willi syndrome is a genetic disorder characterized by intellectual disabilities, hyperphagia, obesity, 
sleep disorders and behavioral problems; the mechanism involves a paternal deletion of chromosomal region 
15q11-q13 harboring snoRNAs SNORD115 (elevated in this study by +84%, FDR = 0.05) and SNORD116 (ele-
vated in this study by +74%, FDR = 0.01). Mice with a deletion of the Snord116 repeat cluster (Snord116del) 
Gene Product Change Ontologies
AD 
assoc Co-exp. PPI
BMP4 bone morphogenetic protein 4 +51%
Regulation
Cell comp.org
Cell Proc
Developmental
Metabolic Processes
83–85,109 absent present
PTMA prothymosin α +48% 110 present present
SOX5 SRY box 5 −45%
Regulation
Developmental
Metabolic Processes
111 absent present
RAB3A ras-related protein 3A −44% 112,113 present present
NRXN3 neurexin-3 α −43% 88–90 present absent
GLIS3 GLIS family zinc finger 3 −42%
Developmental
Multicellular 
Processes
114,115 present present
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 +41%
116 present absent
NMB neuromedin B +41% 117–120 present absent
HGF hepatocyte growth factor +38% 121–124 absent present
GPRC5B G-protein coupled receptor family C group 5 member B −34%
Regulation
Cell comp.org
Immune
Metabolic Proc
Multicellular 
Processes
Response to Stimulus
125 present present
YAP1 yes-associated protein 1 −32% RegulationMetabolic Processes
126 present present
SMAD6 SMAD family member 6 −29%
Regulation
Metabolic Processes
Response to Stimulus
Signaling
127 absent present
GREM2 gremlin 2 −28% 128 present absent
IRS1 insulin receptor substrate 1 −28% Regulation 129 present present
IGFBP2 insulin-like growth factor binding protein 2 +28%
130–133 absent present
CUX2 cut-like homeobox 2 −27%
Regulation
Localization
Metabolic Processes
134 absent present
ZWINT ZW10 interacting kinetochore protein +27%
135 present present
PPARG peroxisome proliferator-activated receptor γ −26%
Regulation
Developmental
Localization
Metabolic Processes
Response to Stimulus
86,87 present present
Table 3. Li-influenced changes in RNA levels of genes implicated in AD.
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show a diurnal disruption in feeding behaviors. Brain transcripts associated with Snord116del show upregulation 
of diurnally regulated genes, particularly Mtor (mammalian target of rapamycin), Crebp (Creb-binding protein), 
and Igf2r (insulin growth factor receptor) as well as clock genes, with accompanying greater body lean-ness 
and increased lipid oxidation during daylight hours55. Clock genes appear to be disrupted in bipolar disorder 
as well56,57, although the relationship is complex58; there is evidence implicating circadian rhythm changes in 
the response to Li59. SNORD115 also regulates maturation of serotonin receptor 2 C (5HT2C) by alternative 
splicing60,61.
It is notable that snoRNAs are active in chromatin modification. Genome wide association studies (GWAS) 
implicate histone methylation pathways as the most likely targets of snoRNA chromatin modification62. In addi-
tion, alternative splicing is likely to be important in bipolar disorder63.
Li influences snoRNA processing in a yeast model64, which may be enlightening to understand potential 
mechanism in mammalian cells. Specifically, Li appears to inhibit the bisphosphate nucleotidase Hal2p. This 
results in accumulation of adenosine 3′,5′-bisphosphate (pAp), which is normally broken down by Hal2p, and 
of pre-snoRNAs. Accumulation of pAp inhibits activities of RNases necessary for processing of snoRNAs. The 
human homologue for Hal2p is 3′(2′), 5′-bisphosphate nucleotidase 1, or PAP phosphatase (BPNT1). Li inhibits 
BPNT1 activity in crude human brain extracts65. Paradoxically, BPNT1 protein levels are reduced in the frontal 
cortex of bipolar patients65. Thus, the specific anti-bipolar activity of Li is unlikely to be a single mechanism.
Although Li influence on miRNA was very limited, some of the specific miRNAs with significantly altered 
expression play roles in neuropsychiatric disorders. For example, miR-10b was elevated 44% by Li treatment. 
Elevated expression of miR-10b, in cerebrospinal fluid (CSF), can serve as a diagnostic feature for Parkinson’s 
disease (PD)66. Paradoxically, miR-10b levels are reduced in PD brain, and greater levels of miR-10b associate 
with later age of motor onset. However, miR-10b is elevated in Huntington’s disease (HD) brains, and reduced 
levels of miR-10b associated with later age of motor onset in HD67,68. miR-24-1 was elevated 42% by Li treatment. 
This miRNA was downregulated in CSF samples of PD subjects69. It was also significantly reduced in CSF of AD 
vs. Control subjects70. miR-24 serves to reduce levels of Aβ through regulating expression of nicastrin71. Li regu-
lation of glutamate metabotropic receptor 7 (GRM7) – a gene significantly associated in a GWAS study on bipolar 
patients – has been shown to act via miR-13472,73.
When we looked at potential networked effects for Li treatment vs. AD, we first note that none of the “core” 
AD genes we examined were altered by Li treatment in our experiment. However, when we examined both 
co-expression and gene product interaction, connections emerged that may be worthy of further investigation, 
particularly the interaction between SNORD14C and APP. Even though our Li treatment did not alter the levels 
of the core AD gene products, we did not test effects under more “pathogenic-like” conditions, such as oxidative 
stress, and it may be the differences between differences (non-stressed vs. stressed cells) that could further eluci-
date important pathways. Several of the connections we found in our network analysis, such as GSK3B, MAPT, 
ADAM17, and PSEN1 are also involved in other dementias than AD. However we hesitate to speculate on appli-
cability of Li to multiple dementia disorders, since none of these were directly influenced by Li treatment in our 
study. Given that we restricted our work to a single differentiated cell line, we anticipate that much more can be 
learned by using other models, such as human primary brain cultures or induced pluripotent stem cell (iPSC) 
neuronal cultures.
Extending the role of Li treatment past bipolar disorder has revealed some challenges for its use. It is well 
known that, in higher doses, Li can be neurotoxic. It can suppress microtubule-associated protein tau and induce 
PD-like tremor and iron accumulation in brain74. Such iron accumulation is accompanied by reduction of levels 
of APP, which acts as an iron efflux protein75. Iron is only one of several metals that play a role in AD, in part due 
to the function of APP as an iron efflux protein75 that also responds to magnesium and lead76,77. Effective use of 
a metal as a drug may need to take into account interplay of multiple metals’ levels in the cells and environment.
Dosing “in the upper therapeutic range” (for bipolar disorder) can associate both with PD and AD-like symp-
toms and FDG-PET readouts, all of which were relieved by reduction of Li dose78. A larger-scale (>50,000 cases) 
Genea Productb Functions
APP amyloid β precursor protein parental protein of neurotoxic/amyloidogenic Aβ peptide and neurotrophic sAPPα
BACE1 β-secretase 1 rate-limiting enzyme in production of Aβ from APP
ADAM9 ADAM metallopeptidase domain 9 α-secretase, non-amyloidogenic cleaving enzyme for APP
ADAM10 ADAM metallopeptidase domain 10 α-secretase, non-amyloidogenic cleaving enzyme for APP
ADAM17 ADAM metallopeptidase domain 17 α-secretase, non-amyloidogenic cleaving enzyme for APP
PSEN1 presenilin 1 critical constituent of γ-secretase complex, which completes APP cleavage processing
MME membrane metalloendopeptidase clearance enzyme for Aβ
IDE insulin degrading enzyme clearance enzyme for Aβ
MAPT microtubule-associated protein τ primary protein constituent of intraneuronal tangles typical of AD
GSK3B glycogen synthase kinase 3β primary kinase contributing to pro-tangle phosphorylation of microtubule-associated protein τ
REST RE1-silencing transcription factor transcription repression, varies significantly with age
Table 4. “Core” AD genes compared to Li-influenced coding and snoRNA sequences. aNo genes in this table 
were significantly influenced by Li treatment in our data. bProduct name as given in NCBI Gene database.
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retrospective study of Taiwanese patients administered Li reported mixed results5. On the other hand. low/
micro-dose treatments improved agitation and stabilized cognitive impairment in AD79,80. When microdose Li 
was applied to animal AD models, it prevented memory loss and AD-like pathology81 as well as improved spatial 
memory and reduced Aβ42-induced neuroinflammation82.
Specific mechanisms of Li activity on AD may be explained by examining some of the Li-influenced coding 
gene products we mention herein. For example, BMP4 reduces hippocampal cell proliferation in animal AD 
models83, and BMP4 is elevated in AD84. Furthermore, APP regulates BMP/SMAD signaling in glial differentia-
tion85. Another gene strongly implicated in AD is PPARγ, whose AD-related activities include possible inhibition 
of β-site amyloid cleaving enzyme 1 (BACE1)86 and SNP-based interaction with apolipoprotein E to alter AD 
risk87, among many other possible connections. Neurexin 3 (NRXN3) contains a polymorphism (rs17757879) 
that protects against AD in male subjects88. Furthermore, toxic Aβ oligomers interact with neurexins and reduce 
NRXN-mediated excitatory presynaptic organization89. Finally, NRXN3 is processed by the same α- and γ- secre-
tases that produce the neurotrophic products of the “non-amyloidogenic” APP processing pathway90, including 
sAPPα. Other gene products we identified have their own potential associations with AD, as well, such as multiple 
snoRNAs that vary according to Braak stage42 and were also altered by Li-treatment in our study.
Our work herein highlights specific RNA species-specific responses to Li treatment, which would fuel mech-
anistic studies. While countless in silico pathways could have been found by examination of multiple databases, 
any claims connecting Li, snoRNAs, and disease states on that basis would be speculative. What we have exper-
imentally discovered is that Li treatment has (at least) two distinct effects on RNA levels. The first is an RNA 
species-independent inverse relationship between RNA length and Li influence on RNA levels. The second is dif-
ferent effect levels by RNA type, irrespective of RNA length. The presence of miRNA as the least-influenced RNA 
type is particularly interesting, since it is in stark contrast against the majority of short RNA species. A different 
approach to investigating miRNA vs. Li treatment further underscored such “resistance” of miRNA to Li. When 
Li treatment response phenotypes in bipolar patients was screened by a large (1,693 sequence) genome-wide 
association study of pre-miRNA genes plus 20 kb flanking sequence, only one pre-miRNA gene had a nominally 
significant (p ≤ 0.05) sequence variation association, but when corrected for multiple comparisons, no polymor-
phisms in pre-miRNA plus flanking sequence showed any association with Li treatment phenotypes91. That study 
compared symptomatic Li response in patients to genetic sequences rather than response in cell culture transcrip-
tome levels. This is not necessarily in conflict with known associations between miRNAs and bipolar disorder 
risk, since risk, progression, and treatment response may each be governed by distinct pathways.
Figure 3. Human hippocampus genetic co-expression network of snoRNA, selected Li-influenced protein 
coding genes and “core” AD genes. Gene symbols and Li-induced fold-change for snoRNAs, “core” AD genes 
(Table 5), and selected Li-influenced genes (Table 3) were analyzed for co-expression in human hippocampus 
by NetworkAnalyst. “Core” AD genes are indicated by star nodes. snoRNAs have square nodes. Color indicates 
log2 fold-change induced by Li treatment, according to legend. White nodes did not appear in our dataset. 
Additional genes inserted by NetworkAnalyst are in Supplementary Table 3.
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 Such differences may suggest potentially useful avenues for investigating short RNA species in the multiple 
disorders currently and potentially treated by Li. What mechanisms could make miRNA less susceptible to Li 
treatment than RNA types of similar length? Are there genetic variations in miRNA response to Li, and do these 
correspond to Li treatment resistance or facilitation in patients? Analogous converse questions could be asked 
regarding snoRNAs and Li. We must point out that our study was on “steady state” RNA levels after one week of 
Li treatment.
While effects of Li on RNA levels were previously reported32–35, our study differs from these prior works in one 
critical and significant way. The preceding studies were limited by using microarray profiling. While the scope 
of microarrays has become quite impressive, they still each have a fixed number (albeit potentially thousands) of 
pre-defined targets. Our survey was high-throughput sequencing with no a-priori presumptions of the presence 
(or absence) of any specific RNA transcript.
We finally need to note that, while ATRA-induced SK-N-SH cultures are often accepted as “neuronal”, they 
are not adult human neurons. Further uses of non-presumptive whole-transcriptome sequencing follow-up to Li 
treatment should be done in other neuronal cell lines and in systems such as neuronal and mixed neuron/glial 
Figure 4. Human hippocampus gene product’s interaction network of snoRNA, selected Li-influenced 
protein coding genes and “core” AD genes. Gene symbols and Li-induced fold-change for snoRNAs, “core” AD 
genes (Table 5), and selected Li-influenced genes (Table 3) were analyzed for product interaction in human 
hippocampus by NetworkAnalyst. This map appears to reveal a multi-target convergence on APP. “Core” AD 
genes are indicated by star nodes. snoRNAs have square nodes. Color indicates log2 fold-change induced by 
Li treatment, according to legend. White nodes did not appear in our dataset. Additional genes inserted by 
NetworkAnalyst are in Supplementary Table 4.
Name Li-induced Change
SCARNA22 +41.7%
SCARNA3 +92.9%
SCARNA6 +52.0%
SNORA37 +69.6%
SNORD104 +83.9%
SNORD46 +48.2%
SNORD60 +42.1%
SNORD94 +63.2%
Table 5. Li-influenced snoRNA sequencesa associated with Braak staging42.
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induced pluripotent stem cell culture, at the very least. Unfortunately, human neuronal cell models are always 
approximations of the actual human brain, as are any animal models. ATRA-induced SK-N-SH cultures have 
important elements of reproducibility and availability, which allows for seminal discoveries to be confirmed and 
later tested in the more costly and difficult models.
Methods
Oversight and approval. All procedures were approved and overseen by the Institutional Biosafety 
Committee, Office of Research Compliance, Indiana University, and Indianapolis, Indiana, USA.
cell culture and treatment. Human neuroblastoma (SK-N-SH) cells were obtained from ATCC and cul-
tured as previously described92, then differentiated by ATRA93. Initial propagation was in Eagle’s modified mini-
mum essential medium (MEM, ThermoFisher, Waltham MA) supplemented with 10% fetal bovine serum (FBS). 
For neuronal differentiation, a stock solution of 0.01 M ATRA (Sigma Prod. No. R2625; >98% HPLC purified), 
was prepared in absolute ethanol and stored in light protected vials at −20 °C and diluted with tissue culture 
medium right before use. Subsequent dilutions were made in growth medium with a final ethanol concentration 
of 0.1% (v/v) which did not affect the described system. During differentiation, cells were switched to MEM 
media with 1% FBS supplemented with 10 µM ATRA for two weeks. Cultures of treated SK-N-SH cells were 
subsequently treated with 1 mM Li chloride (LiCl) or vehicle (distilled water) for an additional week (n = 6 in 
each group). This dose is within a range of reported Li treatment of neuroblastoma cells characterized as “low” 
concentration94,95. Toxicity of Li treatment of neuroblastoma cells was reported to not occur until concentrations 
exceeded 10 mM96.
RnA extraction and sequencing. Total RNA was extracted using the RNeasy mini kit (Qiagen Company, 
Germantown, MD) and ribosomal RNA depleted with Ribo-Zero (Illumina, San Diego CA). Whole transcrip-
tome sequencing was done via SOLiD RNA-Seq kit (ThermoFisher). Briefly, total RNA was fragmented with 
RNase III, hybridized and ligated to SOLiDTM adapters, then subject to reverse transcription with SOLiDTM RT 
primer mix. cDNA was then amplified and sequenced on a 5500xl Genetic Analyzer (ThermoFisher). Identified 
transcripts were classified into RNA types using the typology and databases at, specifically pseudogene.org97, 
HGNC98, and GeneCards99.
Statistical analysis. We analyzed quantitative transcriptome sequencing by edgeR100, which explicitly cal-
culated fold differences in specific RNA levels between Li-treated and untreated cells and determined significance 
(p values and FDR) for each difference. We considered those RNAs that had level differences associated with 
FDR ≤ 0.2 to be “Li-influenced”, regardless of level of influence. We used the mclust43 package to explore possible 
clustered distribution of sequence lengths. Clustering with mclust used a univariate, unequal variances model to 
determine cluster borders and cluster centers were not predetermined.
RNA sequences were typologically classified by referring to three databases, specifically pseudogene.org97, 
HGNC98, and GeneCards99. The presence/absence of Li influence (significant change in RNA level in Li-treated 
vs. control cells) was determined by edgeR and coded as 1 or 0, 1 corresponding to Li-induced net RNA level 
change (either increase or decrease), by individual sequence. Magnitude of change was not considered in this 
study. Examination of the data showed that only 1.3% of sequences’ expression were influenced by Li treat-
ment. Such a low frequency can introduce unacceptable bias into conventional logistic regression, which can 
be corrected by penalized log-likelihood estimation, such as via the logistf R package101. However, when we 
compared conventional and penalized logistic models for bias, we found that conventional methods produced 
no greater bias than did conventional regression for our data. Final analysis was, therefore, done with conven-
tional logistic regression. A full model of “Li influenced ~ log(Length in bp) + RNA type + log(Length) × RNA 
type was constructed and assessed by second-order Akaike information criterion (AICc) using exhaustive com-
binations of predictors102 via the MuMIn R package102. Models were run with Effect contrast coding to explic-
itly compare Li influence of RNA species vs. the overall mean of Li influence frequency103. The effect coded 
model was further used for pairwise comparisons of RNA species by estimated marginal means104. Finally, the 
direction of Li-induced alteration (elevation, no change, or reduction of level) was modeled by multinomial 
logistic regression. Network analysis on selected coding gene products was performed vs. human hippocampus 
co-expression105 or protein-protein interaction106 dataset by NetworkAnalyst107, using the “minimum network” 
algorithm. Gene ontologies were analyzed by the “Gene Ontology System”108. For these utilities, default param-
eters were otherwise used.
Ethical approval and informed consent. All procedures were approved and overseen by the Institutional 
Biosafety Committee (IBC), Office of Research Compliance, Indiana University, and Indianapolis, Indiana, USA. 
No animals or human subjects or samples were used in this work.
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